^
Association details:
| Biomarker: | NRAS mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | pimasertib (AS703026) (MEK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells
Excerpt:
...four NSCLC (H1299, A549, H460, H1975) cell lines with different mutation profiles in KRAS, NRAS, BRAF, PI3KCA and EGFR genes….two cancer cell lines that have a KRAS mutation (LOVO) or a NRAS (H1299) were the most sensitive to MEK inhibition, whereas H1975 and HCT15 that have PI3KCA mutations were the more resistant cells to pimasertib.
DOI:
https://doi.org/10.1002/ijc.28236
